Epstein-Barr virus: novel patented therapeutics

被引：4

作者：

De Paoli, Paolo ^{[1
]}

机构：

[1] Ctr Riferimento Oncol, IRCCS, Sci Direct, I-33081 Aviano, Italy

来源：

EXPERT OPINION ON THERAPEUTIC PATENTS | 2010年 / 20卷 / 06期

关键词：

active immunization; adoptive cellular therapies; antiviral drugs; EBV-associated diseases; Epstein-Barr virus; T-CELL RESPONSES; PHASE-I TRIAL; NATURAL-KILLER; NASOPHARYNGEAL CARCINOMA; RNA INTERFERENCE; IMMUNE-RESPONSE; HERPES-SIMPLEX; GP350; VACCINE; EBV; LYMPHOCYTES;

D O I：

10.1517/13543771003796590

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Importance of the field: Therapeutic strategies against Epstein-Barr virus (EBV) infection and associated cancers are still limited. Due to the primary role of this virus in the pathogenesis of these diseases, molecules interfering with EBV protein functions may represent effective therapeutic tools to treat EBV-associated diseases. Areas covered in this review: Active immunotherapeutic protocols targeting EBV and EBV-associated cancers are reviewed first; then, we reviewed adoptive cellular therapies, innovative pharmacological approaches and other non-conventional therapeutic molecules. What the reader will gain: The published literature, in particular patent publications on EBV therapeutic options, has been searched for relevant information. This information has been organized and discussed. Take home message: Many promising therapeutic opportunities are identified. Among these, vaccination protocols and adoptive cellular therapies are the most advanced and reached Phase I/II clinical trials. Pharmacological approaches are at the moment limited to the laboratory phase.

引用

页码：807 / 818

页数：12

共 105 条

[1]

ADHIKARY D, 2009, Patent No. 2009068615

[2] Immunodominance of Lytic Cycle Antigens in Epstein-Barr Virus-Specific CD4+T Cell Preparations for Therapy [J].

Adhikary, Dinesh ;

Behrends, Uta ;

Boerschmann, Heike ;

Pfuender, Andrea ;

Burdach, Stefan ;

Moosmann, Andreas ;

Witter, Klaus ;

Bornkamm, Georg W. ;

Mautner, Josef .

PLOS ONE, 2007, 2 (07)

[3] Standardized and highly efficient expansion of Epstein-Barr virus-specific CD4+ T cells by using virus-like particles [J].

Adhikary, Dinesh ;

Behrends, Uta ;

Feederle, Regina ;

Delecluse, Henri-Jacques ;

Mautner, Josef .

JOURNAL OF VIROLOGY, 2008, 82 (08) :3903-3911

[4] Epstein-Barr Virus Vaccination of Transplant Candidates: Light at the End of the Tunnel? [J].

Allen, Upton D. .

TRANSPLANTATION, 2009, 88 (08) :976-977

[5]

AMBINDER RF, 2007, EPSTEIN BARR VIRUS H, P204

[6]

BAIOCCHI R, 2009, Patent No. 20090004182

[7]

Baumforth KRN, 1999, J CLIN PATHOL-MOL PA, V52, P307

[8]

Billaud Genevieve, 2009, Infectious Disorders - Drug Targets, V9, P117

[9]

CALIGIURI M, 2007, Patent No. 2007097820

[10]

CALIGIURI M, 2007, Patent No. 20070196389

← 1 2 3 4 5 6 7 8 9 10 →